Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Poly-Tussin is a combination pharmaceutical product developed by **Poly Pharmaceuticals** (also known as Poli Pharmaceutics) for the symptomatic relief of cough and upper respiratory symptoms associated with the common cold, rhinitis, or allergies. It is a multi-ingredient small molecule formulation typically containing **hydrocodone bitartrate**, **chlorpheniramine maleate**, and **phenylephrine hydrochloride**. Hydrocodone acts as a potent antitussive by suppressing the cough reflex in the medullary cough center of the brain. Chlorpheniramine is a first-generation antihistamine that antagonizes H1 receptors to alleviate allergic symptoms such as sneezing and rhinorrhea. Phenylephrine serves as a decongestant by stimulating alpha-1 adrenergic receptors, leading to vasoconstriction of the nasal mucosa and reduction of nasal congestion. The product is marketed as a prescription liquid for oral administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Poly-Tussin.